Bavarian Nordic (NASDAQ: BVNKY) Gains Swissmedic Nod for Chikungunya Vaccine

April 16, 2026

Key Developments Bavarian Nordic (NASDAQ: BVNKY) has secured approval from Swissmedic, the Swiss Agency for Therapeutic Products, for its chikungunya vaccine, VIMKUNYA®. This authorization allows the vaccine to be used for active immunization to protect individuals aged 12 and older against chikungunya virus infection. This regulatory milestone marks a significant advancement for Bavarian Nordic (NASDAQ: BVNKY) as it expands the availability of its recombinant, adsorbed vaccine to an important European…

Read More >>